tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Mayank Mamtani, 219 are a BUY (91.25%), 21 are a HOLD (8.75%).
Analyst Mayank Mamtani, currently employed at B. RILEY, carries an average stock price target met ratio of 35.4% that have a potential upside of 54.4% achieved within 125 days.
Mayank Mamtani’s has documented 485 price targets and ratings displayed on 39 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CYTK, Cytokinetics at 21-Sep-2025.
Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for ALT (ALTIMMUNE) at 11/9/2023. The price target of $8 was fulfilled within 39 days with a profit of $5.55 (226.53%) receiving and performance score of 58.08.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$12
$8.63 (256.08%)
$12
1 years 10 days ago
(25-Sep-2024)
0/2 (0%)
$8.93 (290.88%)
Buy
$2.5
$-0.28 (-10.07%)
2 years 7 months 21 days ago
(15-Feb-2023)
1/1 (100%)
$1.86 (290.63%)
145
Buy
$30
3 years 3 months 14 days ago
(21-Jun-2022)
0/2 (0%)
$22.32 (290.63%)
Hold
$12
$8.63 (256.08%)
5 years 1 months 4 days ago
(01-Sep-2020)
1/2 (50%)
$1.58 (15.16%)
19
Buy
5 years 1 months 5 days ago
(30-Aug-2020)
0/1 (0%)
$59.52 (163.16%)
Which stock is Mayank Mamtani is most bullish on?
Which stock is Mayank Mamtani is most reserved on?
What Year was the first public recommendation made by Mayank Mamtani?
